Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Moderate to Severe Plaque Psoriasis (ESTEEM 1)
NCT01194219Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoint: Proportion of participants achieving >= 75% reduction in Psoriasis Area and Severity Index at 16 weeks. Started Sep 2010; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01194219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194219.